ClinicalTrials.gg
TerminatedNCT06016270Updated Sep 5, 2025

A Study of hSTC810 in Combination With Paclitaxel in Relapsed or Refractory Extensive Stage Small Cell Lung Cancer

A Phase 1/2 interventional study of hSTC810 400 mg + Paclitaxel and hSTC810 800 mg + Paclitaxel in Extensive Stage Small Cell Lung Cancer, sponsored by STCube, Inc.. Terminated at 8 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-05.

Sponsored by STCube, Inc. · Phase 1/2, Interventional, and Treatment

Why this study was terminated
Company strategy

From the registry’s dates

  • Primary completion was Jan 2025, 1 year 9 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
10
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 107 studies in Small Cell Lung Carcinoma with a site in Korea, Republic of — 21 open to participants now, 43 under way, 17 of them phase 3. Small Cell Lung Carcinoma · Korea, Republic of.

Enrollment
97th of 103
10 · median 170
Started
2024
with 5 others
Phase 1/2
16 of 107
5 open now
Registered
82nd of 107
by date

Among the 107 studies in Small Cell Lung Carcinoma with a site in Korea, Republic of, this one is the 97th largest by enrollment of the 103 interventional ones that give a count, is one of 6 that started in 2024, is one of 16 in phase 1/2, and was the 82nd registered.

Small Cell Lung Carcinoma

1,301 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.

Browse Small Cell Lung Carcinoma studies →

Open to participants now

21 of the 107 studies in Small Cell Lung Carcinoma with a site in Korea, Republic of are open now. Recruiting first, the newest first:

16 more — sign in →

All 21 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 265 Small Cell Lung Carcinoma studies recruiting now, 175 (66%) set no upper age limit and 66 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 107 studies in Small Cell Lung Carcinoma with a site in Korea, Republic of, or all of them as a file.
02

Study summary

The purpose of this clinical study is to assess the safety and efficacy of hSTC810 and paclitaxel combination therapy in patients with relapsed or refractory extensive stage small cell lung cancer.

Read the detailed description

The study will be conducted in 2 parts. Phase Ib will evaluate the safety of the combination of hSTC810 with a standard dose of paclitaxel using a 3+3 dose escalation design. Phase II will evaluate the efficacy of hSTC810 + paclitaxel combination therapy using a Simon 2-stage method.

03

Conditions studied

  • Extensive Stage Small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ability to understand and sign an form
  • Male or female ≥ 18 years of age
  • or cytologically confirmed SCLC
  • R/R ES-SCLC on or after platinum-based chemotherapy for SCLC with documented disease progression
  • At least 1 as defined by 1.1
  • Performance Score (ECOG PS) of 0 or 1
  • of at least 3 months
  • Adequate organ function as described in the protocol
  • For female or male patients with : Agree to use throughout the study and at least 5 months after the last dose.

Exclusion criteria

Exclusion Criteria:

  • Known active (carcinomatous meningitis)
  • Known active and uncontrolled central nervous system (CNS)
  • Treatment with immunotherapy, chemotherapy, targeted small molecule therapy, or any other agent \< 14 days prior to initiation of study treatment
  • Treatment with radiation therapy \< 14 days prior to initiation of study treatment
  • Major surgery \< 21 days prior to initiation of study treatment
  • Received \< 30 days prior to initiation of study treatment, including intranasal influenza vaccine
  • History of another primary with protocol-defined exceptions
  • Active or history of disease requiring systemic treatment
  • Receiving high doses of or other medications
  • Active or C infection
  • Active or history of non-infectious pneumonitis requiring treatment with steroids
  • Active uncontrolled viral, fungal, or bacterial infection including tuberculosis
  • Pregnant or breastfeeding female patients
  • History of severe reaction to a monoclonal antibody treatment
  • History of severe hypersensitivity reaction or ≥ Grade 3 adverse event (AE) to paclitaxel treatment
  • History of cerebral vascular event, unstable angina, myocardial infarction, or cardiac symptoms within 6 months prior to screening
  • Corrected for Fridericia's method (QTcF) > 470 ms at screening
  • Lack of resolution of any toxicity to max Grade 1 (except alopecia)
  • Active or history of any condition, therapy, or lab abnormality that may interfere with the patient participation for the full duration of the study
  • Known psychiatric or substance use disorder
  • Positive Coronavirus disease 2019 (COVID-19) test at screening
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    hSTC810 400 mg + Paclitaxel

    hSTC810 400 mg will be administered with a standard dose of paclitaxel

    Drug: hSTC810 400 mg + Paclitaxel

  • Experimental
    hSTC810 800 mg + Paclitaxel

    hSTC810 800 mg will be administered with a standard dose of paclitaxel

    Drug: hSTC810 800 mg + Paclitaxel

Interventions

  • DrughSTC810 400 mg + Paclitaxel

    Drug page: Nelmastobart

    hSTC810 400 mg and paclitaxel 175 mg/m2 will be administered as an intravenous (IV) infusion Paclitaxel: 175 mg/m2 will be administered as an IV infusion

  • DrughSTC810 800 mg + Paclitaxel

    Drug page: Nelmastobart

    hSTC810 800 mg and paclitaxel 175 mg/m2 will be administered as an IV infusion

06

What researchers measure

Primary outcomes

  1. Overall Response Rate (ORR)

    Percentage of patients with confirmed Confirmed Response (CR) or Partial Response (PR) as defined by RECIST 1.1 at 3 months

    Time frame: 3 months

  2. Progression Free Survival (PFS) rate

    Proportion of patients without documented progression of disease and alive at 6 months

    Time frame: 6 months

Secondary outcomes

  1. Safety and tolerability

    Incidence, causality, and nature of Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    Time frame: Up to 4 years

  2. Overall Response Rate (ORR)

    Investigator assessed ORR defined by RECIST 1.1

    Time frame: Up to 4 years

  3. Duration of Response (DoR)

    Time from the date of first documented CR or PR until the date of documented progression or death

    Time frame: Up to 4 years

  4. Progression Free Survival (PFS)

    Time from first dose until the date of objective disease progression or death

    Time frame: Up to 4 years

  5. Clinical Benefit Rate (CBR)

    Percentage of evaluable patients with CR, PR, or Stable Disease (SD) lasting ≥ 24 weeks

    Time frame: Up to 4 years

  6. Overall Survival (OS)

    Time from first dose of study drug until the date of death

    Time frame: Up to 4 years

  7. Overall Survival (OS) rate

    Proportion of patients alive at 12 months after the first dose of study drug

    Time frame: 12 months

  8. Maximum plasma concentration (Cmax)

    Maximum plasma concentration of hSTC810 to evaluate PK parameters

    Time frame: Up to 21 days

  9. Area under the concentration-time curve from 0 to 21 days (AUC0-21)

    AUC from 0 to 21 days to evaluate PK parameters

    Time frame: Up to 21 days

  10. Area under the concentration-time curve extrapolated from 0 to infinity (AUCo-inf)

    AUC from time 0 to infinity to evaluate total drug exposure over time

    Time frame: Up to 21 days

  11. Incidence of anti-drug antibodies (ADA)

    Number and percentage of patients with positive ADAs

    Time frame: Up to 4 years

07

Study locations

8 sites
  • Tisch Cancer Institute at Mount Sinai
    New York, New York 10029, United States
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Korea University Anam Hospital
    Seoul, 02841, South Korea
  • Seoul National University Hospital
    Seoul, 03080, South Korea
  • Asan Medical Center
    Seoul, 05505, South Korea
  • Samsung Medical Center
    Seoul, 06351, South Korea
  • Seoul National University Bundang Hospital
    Seoul, 13620, South Korea
  • The Catholic University of Korea St. Vincent's Hospital
    Suwon, 16247, South Korea
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2024 to primary completion in Jan 2025, 11 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 17, 2023
First posted
Aug 29, 2023
StartActual
Feb 13, 2024
Primary completionActual
Jan 23, 2025
CompletionActual
Aug 25, 2025
Last update
Sep 5, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 5, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06016270
Lead sponsor
STCube, Inc.
Responsible party
Sponsor
First posted
Aug 29, 2023
Start date
Feb 13, 2024
Primary completion
Jan 23, 2025
Completion
Aug 25, 2025
Last update
Sep 5, 2025

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nelmastobart

Start the discussion